Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 3

3(50.0%)

Phase 2

2(33.3%)

Phase 1

1(16.7%)

6Total

Phase 3(3)

Phase 2(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02882191Phase 2Completed

Evaluation of the Efficacy and Safety of LevoCept

Role: lead

NCT02446821Phase 2Completed

Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception

Role: lead

NCT03633799Phase 3Active Not Recruiting

Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS

Role: lead

NCT03785366Phase 3Completed

A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs)

Role: lead

NCT04457076Phase 3Not Yet Recruiting

Evaluation of the Efficacy, Safety, and Tolerability of LevoCept

Role: lead

NCT02167763Phase 1Completed

Comparative Study of the VeraCept Low-Dose Intrauterine Copper Contraceptive vs. the TCu380 Copper IUD

Role: lead

All 6 trials loaded